Foundation Medicine Inc (NASDAQ:FMI) SVP Robert W. Hesslein sold 1,864 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $64.00, for a total transaction of $119,296.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Foundation Medicine Inc (FMI) traded up $0.45 during mid-day trading on Wednesday, reaching $63.05. 184,187 shares of the company were exchanged, compared to its average volume of 338,680. Foundation Medicine Inc has a 12 month low of $17.10 and a 12 month high of $70.75. The company has a market capitalization of $2,290.00, a P/E ratio of -14.11 and a beta of -0.01. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47.

Foundation Medicine (NASDAQ:FMI) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.06) by $0.16. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. The company had revenue of $42.66 million during the quarter, compared to the consensus estimate of $37.99 million. During the same period in the prior year, the firm earned ($0.90) earnings per share. Foundation Medicine’s revenue was up 45.0% on a year-over-year basis. equities research analysts anticipate that Foundation Medicine Inc will post -4.44 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Chevy Chase Trust Holdings Inc. increased its stake in shares of Foundation Medicine by 1.1% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 1,059,141 shares of the company’s stock valued at $42,572,000 after purchasing an additional 11,934 shares in the last quarter. Discovery Group I LLC increased its stake in shares of Foundation Medicine by 0.9% during the third quarter. Discovery Group I LLC now owns 836,986 shares of the company’s stock valued at $33,647,000 after purchasing an additional 7,181 shares in the last quarter. Oppenheimer & Co. Inc. increased its stake in shares of Foundation Medicine by 5.8% during the third quarter. Oppenheimer & Co. Inc. now owns 723,480 shares of the company’s stock valued at $29,084,000 after purchasing an additional 39,390 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Foundation Medicine by 8.2% during the second quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock valued at $25,096,000 after purchasing an additional 47,843 shares in the last quarter. Finally, Lord Abbett & CO. LLC increased its stake in shares of Foundation Medicine by 146.0% during the second quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock valued at $23,024,000 after purchasing an additional 343,770 shares in the last quarter. 32.68% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently issued reports on FMI shares. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Saturday, September 9th. Zacks Investment Research downgraded shares of Foundation Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $45.33.

WARNING: “Foundation Medicine Inc (FMI) SVP Robert W. Hesslein Sells 1,864 Shares” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/03/foundation-medicine-inc-fmi-svp-robert-w-hesslein-sells-1864-shares.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.